Apogee Therapeutics Reports $65M Net Loss in Q3 2025, Increases R&D Spending

Apogee Therapeutics, Inc. reported significant financial results for the third quarter of 2025, revealing a net loss of $65.0 million, compared to a net loss of $49.0 million for the same period in 2024. The company's total operating expenses increased to $71.3 million from $58.7 million year-over-year, driven primarily by a rise in research and development costs, which reached $54.2 million, up from $45.7 million. This increase reflects ongoing investments in the development of its lead product candidate, APG777, and other pipeline programs. General and administrative expenses also rose to $17.1 million from $13.0 million, attributed to higher personnel costs and equity-based compensation.

In the nine months ending September 30, 2025, Apogee's net loss totaled $186.5 million, significantly higher than the $114.9 million loss reported in the same period of 2024. Total operating expenses for this period were $207.5 million, compared to $141.0 million in the prior year. The increase in expenses was largely due to heightened research and development activities, particularly for APG777, which saw costs rise by $30.3 million as the company advanced its clinical trials.

Operationally, Apogee has made strides in its clinical programs, particularly with APG777, which targets IL-13 for the treatment of atopic dermatitis. The company announced positive interim results from its Phase 2 APEX trial, demonstrating significant efficacy compared to placebo. The trial met its primary endpoint, with a 71.0% reduction in the Eczema Area Severity Index (EASI) score for patients treated with APG777. The company is also advancing other candidates, including APG990 and APG333, with ongoing clinical trials expected to yield further data in 2026.

As of September 30, 2025, Apogee reported cash and cash equivalents of $107.9 million, alongside $419.4 million in marketable securities. The company anticipates that its current financial resources, bolstered by a recent public offering that raised approximately $324.1 million, will be sufficient to fund operations through at least the second half of 2028. However, Apogee cautioned that it will require substantial additional funding to support its ongoing development efforts and achieve commercialization of its product candidates. The company has not yet generated revenue from product sales and does not expect to do so for several years.